References
- Rogozhin DV, Bulycheva IV, Konovalov DM, et al. Classical osteosarcoma in children and adolescent. Arkh patol. 2015;77:68–74.
- Murakami T, Igarashi K, Kawaguchi K, et al. Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. Oncotarget. 2017 ;8:8035–8042.
- Kanwal R, Gupta K., Gupta S. Cancer epigenetics: an introduction In: Verma M, editor. Cancer epigenetics: risk assessment, diagnosis, treatment, and prognosis. New York, NY: Springer New York; 2015. p. 3–25.
- Morrow JJ, Khanna C. Osteosarcoma genetics and epigenetics: emerging biology and candidate therapies. Crit Rev Oncog. 2015;20:173–197.
- Kinnaird A, Zhao S, Wellen KE, et al. Metabolic control of epigenetics in cancer. Nat Rev Cancer.. 2016;16:694.
- Jones PA, Issa J-PJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630.
- Wang R, Xin M, Li Y, et al. The Functions of Histone Modification Enzymes in Cancer. CPPS. 2016;17:438–445.
- Shanmugam MK, Arfuso F, Arumugam S, et al. Role of novel histone modifications in cancer. Oncotarget. 2018;9:11414–11426.
- Hans F, Dimitrov S. Histone H3 phosphorylation and cell division. Oncogene. 2001;20:3021–3027.
- Lee CC, Lin YH, Chang WH, et al. Squamocin modulates histone H3 phosphorylation levels and induces G1 phase arrest and apoptosis in cancer cells. BMC cancer. 2011;11:58.
- Espino PS, Pritchard S, Heng HH, et al. Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells. Int J Cancer. 2009;124:562–567.
- McAndrews KM, LeBleu VS, Kalluri R. SIRT1 regulates lysosome function and exosome secretion. Dev Cell. 2019;49:302–303.
- Yang H, Bi Y, Xue L, et al. Multifaceted modulation of SIRT1 in cancer and inflammation. Crit Rev Oncog.. 2015;20:49–64.
- Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149–159.
- Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23:2369–2380.
- Zhang N, Xie T, Xian M, et al. SIRT1 promotes metastasis of human osteosarcoma cells. Oncotarget. 2016;7:79654–79669.
- Chen J, Cao L, Li Z, et al. SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake. Hum Cell. 2019 ;32:193–201.
- Yu XJ, Guo XZ, Li C, et al. SIRT1-ZEB1-positive feedback promotes epithelial-mesenchymal transition process and metastasis of osteosarcoma. J Cell Biochem. 2019;120:3727–3735.
- He S, Wang Z, Tang H, et al. MiR-217 inhibits proliferation, migration, and invasion by targeting SIRT1 in osteosarcoma. Cancer Biother Radiopharm. 2019;34:264–270.
- Luo H, Shenoy AK, Li X, et al. MOF acetylates the histone demethylase LSD1 to suppress epithelial-to-mesenchymal transition. Cell reports. 2016;15:2665–2678.
- Machida K, Liu B. Binding assays using recombinant SH2 domains: far-Western, pull-down, and fluorescence polarization. Methods Mol Biol. 2017;1555:307–330.
- Liu Y, Long YH, Wang SQ, et al. JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity. Oncogene. 2019 ;38:980–997.
- Ish-Shalom S, Lichter A. Analysis of fungal gene expression by real time quantitative PCR. Methods Mol Biol. 2010;638:103–114.
- La Noce M, Paino F, Mele L, et al. HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. J Exp Clin Cancer Res. 2018;37:296.
- He C, Liu C, Wang L, et al. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma. Cell death Dis. 2019;10:65.
- Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009;69:1702–1705.
- Feng H, Guo P, Wang J, et al. Expression of Leptin and Sirtuin-1 is associated with poor prognosis in patients with osteosarcoma. Pathol Res Pract. 2016;212:319–324.
- Jia D, Niu Y, Li D, et al. lncRNA C2dat1 promotes cell proliferation, migration, and invasion by targeting miR-34a-5p in osteosarcoma cells. Oncol Res. 2018;26:753–764.
- Fyodorov DV, Zhou BR, Skoultchi AI, et al. Emerging roles of linker histones in regulating chromatin structure and function. Nat Rev Mol Cell Biol. 2018;19:192–206.
- Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. TIG. 2004;20:214–220.
- Bhat P, Kriel J, Shubha Priya B, et al. Modulating autophagy in cancer therapy: advancements and challenges for cancer cell death sensitization. Biochemical pharmacology. 2018;147:170–182.
- Lozy F, Karantza V. Autophagy and cancer cell metabolism. Semin Cell Dev Biol. 2012;23:395–401.
- White E. The role for autophagy in cancer. J Clin Invest. 2015;125:42–46.
- Xiong H, Ni Z, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017;36:3528.
- Wang J, Li J, Cao N, et al. Resveratrol, an activator of SIRT1, induces protective autophagy in non-small-cell lung cancer via inhibiting Akt/mTOR and activating p38-MAPK. OTT. 2018;11:7777–7786.
- Niu NK, Wang ZL, Pan ST, et al. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Drug Des Dev Ther. 2015;9:1555–1584.
- Levine B, Kroemer G. Biological functions of autophagy genes: a disease perspective. Cell. 2019;176:11–42.
- Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19:349–364.